A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Roswell Park Cancer Institute
Hackensack Meridian Health
Acerta Pharma BV
M.D. Anderson Cancer Center
University of Chicago
Gilead Sciences
University of Washington
Mayo Clinic
Acerta Pharma BV
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Roswell Park Cancer Institute
University of Maryland, Baltimore
City of Hope Medical Center
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
University College, London
BeiGene
BeiGene
Columbia University
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Rochester
City of Hope Medical Center
Stanford University
Mayo Clinic
University of Nebraska
Weill Medical College of Cornell University
University of Nebraska
Eastern Cooperative Oncology Group
TG Therapeutics, Inc.
Abramson Cancer Center at Penn Medicine
Brown University
Karyopharm Therapeutics Inc
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Mayo Clinic
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Northwestern University
Roswell Park Cancer Institute
Cancer Research UK
ADC Therapeutics S.A.
Barbara Ann Karmanos Cancer Institute
Dana-Farber Cancer Institute
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Pharmacyclics LLC.
Dana-Farber Cancer Institute